Tumor Immunology and Immunotherapy Program

肿瘤免疫学和免疫治疗项目

• 批准号: 10267045
• 负责人: Xuefang Cao
• 金额: $ 5.1万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-08 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10267045
• 关键词: Adverse effects; Antitumor Response; Baltimore; Basic Science; Biometry; Cancer Burden; Catchment Area; Cells; Cigarette; Collaborations; Communities; Community Outreach; Comprehensive Cancer Center; County; Development; Direct Costs; Disease; Doctor of Medicine; Doctor of Philosophy; Flow Cytometry; Funding; Funding Agency; Genomics; Goals; Grant; Human; Image; Immune; Immunosuppression; Immunotherapy; Infection; Inflammation; Inflammatory Response; Institutes; Interdisciplinary Study; Investigational Therapies; Journals; Knowledge; Laboratories; Malignant - descriptor; Malignant Neoplasms; Maryland; Medical; Medical center; Molecular Biology; Monitor; NCI Center for Cancer Research; Pathology; Peer Review; Pharmacy Schools; Population Sciences; Public Health Schools; Publications; Regulatory Pathway; Research; Research Personnel; Research Support; Role; School Dentistry; Services; Signal Transduction; Source; System; Therapeutic; Translating; Treatment Protocols; Universities; acronyms; base; biobank; cancer cell; cancer immunotherapy; cell growth; college; community engagement; faculty support; hormone related cancer; immunoregulation; innovation; medical schools; member; neoplasm immunotherapy; novel diagnostics; novel therapeutics; programs; structural biology; translational clinical trial; tumor; tumor immunology; virology

14.0 Abstract: Tumor Immunology and Immunotherapy (TII) Program The TII Program is an interdisciplinary program that pursues highly innovative basic science research and translational/clinical trials. The overall goal of the TII Program is to develop and implement immune-based strategies to monitor and treat cancer. To achieve this goal, the program focuses on three research aims: Aim 1: Cell-based and regulatory pathway-targeted cancer immunotherapies—Develop cell-based and regulatory pathway-targeted cancer immunotherapies that are capable of reducing or monitoring malignant cell growth. Aim 2: Calibrating immune regulation—Develop strategies to overcome tumor-induced immunosuppression and to mitigate immunotherapy-related adverse effects. Aim 3: Cancer and inflammation—Elucidate the roles of infection and inflammatory responses in cancer development. The TII Program is an interdisciplinary research and educational program. Program members are dedicated to understanding the immune regulation of malignant disease and translating this knowledge into the development of novel diagnostic and treatment regimens. The TII Program has 35 members, including 18 full members and 17 associate members, who conduct cancer- focused research supported by $16.6 million annual direct cost funding ($21.7 million total), including $1.9 million (11.2%) from NCI and $10.5 million from other peer-reviewed sources. TII Program members receive $4.3 million annually from non–peer-reviewed funding sources. During this funding period, TII members authored 371 cancer-related publications, of which 15% resulted from intraprogrammatic, 30% from interprogrammatic, and 6% from intra and interprogrammatic collaborations; 64% of publications include collaborations with external investigators, reflecting the high national impact of the TII Program, and 14% of TII publications were in journals with an impact factor ≥10. The research efforts of TII faculty are supported by extensive use of all shared services. The TII Program is integrated with the other research programs at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) and TII interacts with Community Outreach and Engagement (COE) as a bridge to identify the needs of communities in our catchment area.

14.0摘要：肿瘤无限疗法和免疫疗法（TII）计划 TII计划是一项实习生计划，旨在追求高度创新的基础科学研究和 转化/临床试验。 监测和治疗癌症以实现这一目标的策略，该计划的重点是目的：AIM 1： 基于细胞的和调节途径为靶向癌症的癌症 - 基于细胞和调节 靶向途径的Caner Imunotherapies能够减少或监测恶性细胞生长。 目标2：校准免疫调节开发策略以克服肿瘤诱导的免疫选择 并减轻免疫疗法相关的不良反应。 癌症发展中的感染和炎症反应。 和教育计划。 疾病并将这种知识转化为新的诊断和治疗方案的发展 TII计划有35名成员，包括18个正式成员和17名助理成员，他们进行癌症 - 重点研究由1660万美元的年度直接成本资金（总计2170万美元）支持，其中包括190万美元 （11.2％）来自NCI和其他同行评审的1,050万美元。 每年来自未经审查的资金来源。 与癌症相关的出版物，其中15％是由术中产生的 6％的Intra和Intervogmatic合作； 64％的出版物包括与外部合作 调查人员反映了TII计划的重大影响，而TII出版物中有14％在期刊上 效果因子≥10。 服务计划与马里兰州大学的其他研究计划集成 以及Stewart Greenebaum综合癌症中心（UMGCCC）和TII与COMUNITY相互作用 外展和英语（COE）是确定我们集水区社区需求的桥梁。